At a glance
ClinicalIndex Comparison RecordPhase 2Active· 21 target
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Nivolumab 240mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Aug 1, 2018·Updated May 6, 2026
In Brief
A Phase 2 clinical trial evaluating Nivolumab and Relatlimab for Gastroesophageal Cancer and Immune Checkpoint Inhibition. Active but no longer recruiting, targeting 21 participants across 3 sites.
Detailed Summary
This is a Phase 1B study assessing the safety of immune checkpoint inhibition after SBRT in patients with recurrent or metastatic gastroesophageal cancer (limited metastatic disease).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2Active
2019202020212022202320242025202620272028
First PostedAug 2018
Enrollment StartMar 2019
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2027
First PostedAug 1, 2018
Enrollment StartMar 6, 2019
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2027
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 7.9 years agoPrimary completion in 5 months
Interventions
Nivolumabdrug
240mg administered IV over 30 minutes every 2 weeks for one year
Relatlimabdrug
every 2 weeks for one year